Does Transcatheter Therapy of Severe Tricuspid Regurgitation Help Patients?

It might be so: Patients receiving transcatheter interventions were less likely to die or be hospitalized for heart failure than those on medical therapy alone, in an observational study.

Although severe symptomatic tricuspid regurgitation (TR) is associated with reduced survival, it is often treated conservatively. In this observational study, investigators analyzed registry data from 22 centers performing investigational and off-label interventions for TR and compared those outcomes with consecutive patients treated medically at two institutions. Propensity-score matching was used to identify 268 patient pairs for analysis.

Patients' mean age was 76, 57% were women, and >90% had functional etiology. Transcatheter therapy successfully reduced TR to moderate or less in 86% of patients. Among patients who received transcatheter therapy, 23% underwent concomitant mitral repair. One-year estimated survival without rehospitalizat…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)